Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
As the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors brings new hope to clinical practice. However, a considerable portion of patients do not response to this therap...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.955163/full |
| _version_ | 1828114476490031104 |
|---|---|
| author | Chao Cheng Lingdun Zhuge Xin Xiao Siyuan Luan Yong Yuan |
| author_facet | Chao Cheng Lingdun Zhuge Xin Xiao Siyuan Luan Yong Yuan |
| author_sort | Chao Cheng |
| collection | DOAJ |
| description | As the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors brings new hope to clinical practice. However, a considerable portion of patients do not response to this therapy, meanwhile most patients sensitive to PD-1 or PD-L1 antibody initially will develop resistance to the treatment eventually. To break through the limits of clinical effect, it is of critical importance to make a profound understanding of the mechanisms of so called primary resistance and acquired resistance. Subsequently, exploring potent predictors to identify suitable patients for anti-PD-1/PD-L1 treatment and investigating efficient strategies to overcome drug resistance will be helpful to expend the benefit of immunotherapy. In the present view, we summarized the potential predictive factors for anti-PD-1/PD-L1 immunotherapy in EC, and demonstrated the plausible mechanisms of resistance to PD-1/PD-L1 blockade as well as its feasible solutions. |
| first_indexed | 2024-04-11T12:25:56Z |
| format | Article |
| id | doaj.art-92d7df97b20341ea9efb94db9a83cf24 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T12:25:56Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-92d7df97b20341ea9efb94db9a83cf242022-12-22T04:23:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.955163955163Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancerChao Cheng0Lingdun Zhuge1Xin Xiao2Siyuan Luan3Yong Yuan4Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, ChinaAs the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors brings new hope to clinical practice. However, a considerable portion of patients do not response to this therapy, meanwhile most patients sensitive to PD-1 or PD-L1 antibody initially will develop resistance to the treatment eventually. To break through the limits of clinical effect, it is of critical importance to make a profound understanding of the mechanisms of so called primary resistance and acquired resistance. Subsequently, exploring potent predictors to identify suitable patients for anti-PD-1/PD-L1 treatment and investigating efficient strategies to overcome drug resistance will be helpful to expend the benefit of immunotherapy. In the present view, we summarized the potential predictive factors for anti-PD-1/PD-L1 immunotherapy in EC, and demonstrated the plausible mechanisms of resistance to PD-1/PD-L1 blockade as well as its feasible solutions.https://www.frontiersin.org/articles/10.3389/fonc.2022.955163/fullesophageal cancerimmunotherapyresistanceimmune checkpoint inhibitorsprogrammed death 1programmed death-ligand 1 |
| spellingShingle | Chao Cheng Lingdun Zhuge Xin Xiao Siyuan Luan Yong Yuan Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer Frontiers in Oncology esophageal cancer immunotherapy resistance immune checkpoint inhibitors programmed death 1 programmed death-ligand 1 |
| title | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer |
| title_full | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer |
| title_fullStr | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer |
| title_full_unstemmed | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer |
| title_short | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer |
| title_sort | overcoming resistance to pd 1 pd l1 inhibitors in esophageal cancer |
| topic | esophageal cancer immunotherapy resistance immune checkpoint inhibitors programmed death 1 programmed death-ligand 1 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.955163/full |
| work_keys_str_mv | AT chaocheng overcomingresistancetopd1pdl1inhibitorsinesophagealcancer AT lingdunzhuge overcomingresistancetopd1pdl1inhibitorsinesophagealcancer AT xinxiao overcomingresistancetopd1pdl1inhibitorsinesophagealcancer AT siyuanluan overcomingresistancetopd1pdl1inhibitorsinesophagealcancer AT yongyuan overcomingresistancetopd1pdl1inhibitorsinesophagealcancer |